Antiaging Quantum Living Inc.
AAQLdata completeness 75%10 fiscal years on fileData notes: no data for concept 'totalDebt'; no data for concept 'investmentsAtFairValue'; no data for concept 'netInvestmentIncome'; no data for concept 'gainsOnRealEstateSales'; no data for concept 'dividendsPaid'; no data for concept 'interestExpense'
| Figure | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|
| Revenue | $7,4001 | $13,6002 | $7,4993 | $817,8984 | $1.03M4 |
| Net income | −$43,4365 | −$36,6306 | −$412,9717 | −$720,4098 | −$837,6468 |
| Operating cash flow | −$41,1409 | −$38,21510 | −$649,41311 | −$900,28012 | −$171,02512 |
| Capital expenditure | $95013 | — | — | — | — |
| Free cash flow (derived) | −$42,0909 | — | — | — | — |
| Total debt | — | — | — | — | — |
| Cash & equivalents | $14,26914 | $35415 | $166,55216 | $370,54917 | $503,48617 |
| Diluted shares | 30.0M | 30.0M | 30.0M | 30.0M | 31.5M |
Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).
10 shares is a claim on −$0.21 of net worth that earned you −$0.27 last year.
Not enough data in the filings for a return-on-capital reading.
seeing a moat in the numbers →Share count is up 5% over 5 years — owners have been diluted. Worth asking what they got for it.
reading capital allocation →Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.
Different models answer different questions — which to trust when →
- 10-K · period ending 2022-03-31 · accession 0001493152-23-024592 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K/A · period ending 2023-03-31 · accession 0001493152-24-020108 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2024-03-31 · accession 0001641172-25-017604 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2025-03-31 · accession 0001493152-26-033212 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2022-03-31 · accession 0001493152-23-024592 (NetIncomeLoss)
- 10-K/A · period ending 2023-03-31 · accession 0001493152-24-020108 (NetIncomeLoss)
- 10-K · period ending 2024-03-31 · accession 0001641172-25-017604 (NetIncomeLoss)
- 10-K · period ending 2025-03-31 · accession 0001493152-26-033212 (NetIncomeLoss)
- 10-K · period ending 2022-03-31 · accession 0001493152-23-024592 (NetCashProvidedByUsedInOperatingActivities)
- 10-K/A · period ending 2023-03-31 · accession 0001493152-24-020108 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2024-03-31 · accession 0001641172-25-017604 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2025-03-31 · accession 0001493152-26-033212 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2022-03-31 · accession 0001493152-23-024592 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2022-03-31 · accession 0001493152-23-024592 (CashAndCashEquivalentsAtCarryingValue)
- 10-K/A · period ending 2023-03-31 · accession 0001493152-24-020108 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2024-03-31 · accession 0001641172-25-017604 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2025-03-31 · accession 0001493152-26-033212 (CashAndCashEquivalentsAtCarryingValue)